10 Oral: AKY-1189, a novel, first-in-class miniprotein radiopharmaceutical designed to deliver Actinium-225 (225Ac) to Nectin-4 expressing tumors with broad therapeutic applications in metastatic urothelial carcinoma (mUC) and other Nectin-4 expressing tumors
Titel:
10 Oral: AKY-1189, a novel, first-in-class miniprotein radiopharmaceutical designed to deliver Actinium-225 (225Ac) to Nectin-4 expressing tumors with broad therapeutic applications in metastatic urothelial carcinoma (mUC) and other Nectin-4 expressing tumors
Auteur:
Sathekge, M. Ndlovu, H. Kabunda, J. Mdlophane, A. Ramonaheng, K. Mdanda, S. Shungube, M. Mzizi, Y. Qebetu, M. Sebatana, R. Mokoala, K. Mashigoane, K. Zane, K. More, S. Vorster, M. Nasr, K. Morley, T. Kovacs, J. Horton, J. Herrmann, K.